This study presents the most comprehensive longitudinal plasma proteomic dataset for ccRCC to date, defining robust circulating protein biomarker signatures for both localized and metastatic disease, and establishing a proteomic landscape for minimally invasive, real-time monitoring and improved clinical management of ccRCC patients.
It is argued that clinically useful signatures should be question-specific, stage-aware, and specimen-aware rather than universal multi-analyte panels and the need for prospective validation across clinically diverse populations is argued.
Ke Xu, Yu Liu, Yuan Peng et al.· Biofactors· 0 citations
This review evaluates biomarkers at three clinical decision points: characterization of an indeterminate renal mass; recurrence-risk assessment and adjuvant treatment selection after nephrectomy; and first-line regimen selection in metastatic ccRCC.
Hadi Al Etri, Lea Al Zoghby, M. Zoghbi et al.· Genes· 0 citations
Findings support the reproducibility of the DCCD-associated prognostic framework and identify SMIM24 as a candidate suppressor of ccRCC aggressiveness and PD-L1 expression, potentially acting in part through reduced STAT3 activation.
A tissue microarray comprising pRCC tumors and adjacent normal kidney tissue from 102 patients treated at Vanderbilt University Medical Center was assembled andMultivariate machine learning modeling showed that spatial clusters were more strongly predictive of clinical outcomes compared to other feature types.
W. J. Brewer, Joseph A. Vento, Ezra Blumenthal et al.· The Oncologist· 0 citations
This review systematically evaluate recent progress in machine-learning-based screening of diagnostic biomarkers for SCLC across transcriptomic, exosomal RNA, proteomic, metabolomic, metabolomic, and DNA methylation datasets and critically appraise the diagnostic accuracy, validation rigor, and reproducibility of publi...
M. Masood, Yong Dai· International Journal of Sci...· 0 citations
This work consolidates recent advances in circRNA research across preoperative, postoperative, drug resistance, and recurrence settings, providing a framework for non-invasive diagnosis, clinical decision-making, and outcome prediction in BC management.
Chun-Ming Wang, Xu Wang, Yu-Bo Liu et al.· Oncology Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.